APA (7th ed.) Citation

Jeger, S., Schönborn-Kellenberger, O., De Winter, H., Steeghs, N., Gort, E., Gomez-Roca, C., . . . Cassier, P. (2021). 170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors. Annals of Oncology, 32, S1456. https://doi.org/10.1016/j.annonc.2021.10.189

Chicago Style (17th ed.) Citation

Jeger, S., et al. "170TiP A Phase I Study to Characterize the Safety and Tolerability of MP0317, a Tumor Targeting FAP Dependent CD40 Agonist DARPin®, in Patients with Relapsed/refractory Solid Tumors." Annals of Oncology 32 (2021): S1456. https://doi.org/10.1016/j.annonc.2021.10.189.

MLA (9th ed.) Citation

Jeger, S., et al. "170TiP A Phase I Study to Characterize the Safety and Tolerability of MP0317, a Tumor Targeting FAP Dependent CD40 Agonist DARPin®, in Patients with Relapsed/refractory Solid Tumors." Annals of Oncology, vol. 32, 2021, p. S1456, https://doi.org/10.1016/j.annonc.2021.10.189.